research use only
Cat.No.S7072
|
In vitro |
Water : 29 mg/mL
DMSO
: 15 mg/mL
(101.95 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 147.13 | Formula | C5H9NO4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 6384-92-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | SMILES | CNC(CC(=O)O)C(=O)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
NMDA receptor
|
|---|---|
| In vitro |
NMDA (N-Methyl-D-aspartic acid) is an excitatory amino acid neurotransmitter that specifically binds to the NR2 subunits of its receptor without affecting other glutamate receptors (such as those for AMPA and kainate). This compound stimulates the opening of a non-specific cation channel, allowing the passage of Ca2+ and Na2+ into the cell and K+ out of the cell. Its activation can produce excitatory postsynaptic potentials (EPSP) and trigger an increase in intracellular Ca2+ content, which may further participate in various signaling pathways. The NMDA receptor plays a key role in a wide range of physiological (e.g., long-term potentiation and neuronal plasticity) and pathological processes (e.g., excitotoxicity and epilepsy).
|
References |
(data from https://clinicaltrials.gov, updated on 2025-09-17)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07122895 | RECRUITING | Schizophrenia |
China Medical University Hospital |
2025-09-16 | PHASE2 |
| NCT06574360 | RECRUITING | Schizophrenia |
China Medical University Hospital |
2024-09-23 | PHASE2 |
| NCT04372615 | RECRUITING | Autoimmune Encephalitis; Encephalitis |
University of Utah |
2022-03-30 | PHASE2 |
| NCT05181189 | NOT_YET_RECRUITING | Omega 3 Fatty Acids; Dementia |
Chang Gung Memorial Hospital |
2026-08 | PHASE2 |
| NCT06021197 | RECRUITING | Schizophrenia |
China Medical University Hospital |
2023-10-12 | PHASE2 |
| NCT07093333 | RECRUITING | Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE); Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease; Autoimmune Encephalitis |
Arialys Australia Pty Ltd |
2026-05-15 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.